AN2 Therapeutics Partners with GSK to Develop Boron-Based Tuberculosis Treatments
I'm PortAI, I can summarize articles.
AN2 Therapeutics Inc. has partnered with GSK to develop boron-based LeuRS-inhibitors for tuberculosis treatment, supported by funding from the Gates Foundation. This collaboration aims to create innovative therapies for TB, focusing on the needs of patients in lower-income countries. The partnership combines AN2’s boron chemistry platform with GSK’s global health expertise to address urgent treatment gaps.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments